Palo Alto, Calif. — December 22, 2025 — Leads & Copy — BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced on December 18, 2025, that its compensation committee approved equity grants to 9 new employees. The grants consist of restricted stock units for an aggregate of 29,472 shares of the Company’s common stock.
The shares will vest according to the following schedule: One-fourth of the shares underlying each employee’s restricted stock units will vest on November 16, 2026, with one-twelfth of the remaining shares vesting quarterly thereafter. Vesting is contingent upon the employee’s continued employment with BridgeBio or one of its subsidiaries on the specified vesting dates.
The awards were granted as an inducement material to the employees entering into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. BridgeBio’s board of directors adopted the Plan in November 2019, and it was amended and restated on February 10, 2023, and December 13, 2023.
BridgeBio Pharma, Inc. (BridgeBio) is a biopharmaceutical company focused on discovering, creating, testing, and delivering medicines for genetic diseases. Founded in 2015, BridgeBio’s pipeline includes programs ranging from early science to advanced clinical trials.
Bubba Murarka, Executive Vice President, Corporate Development, can be reached at contact@bridgebio.com or (650)-789-8220.
Chinmay Shukla, Senior Vice President, Strategic Finance, can be reached at ir@bridgebio.com.
Source: BridgeBio Pharma, Inc.
